Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03875313 · ClinicalTrials.gov registry record · Phase 1
Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors
A Phase 1 study, sponsored by Calithera Biosciences.
- Terminated
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT03875313 is a Phase 1 study that was terminated before completion, run by Calithera Biosciences. The registered enrollment target is 33 participants.
The verdict
NCT03875313, a Phase 1 study, was terminated before completion, sponsored by Calithera Biosciences.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
This is a Phase 1b/2 study to determine the recommended phase 2 dose (RP2D), safety and tolerability, pharmacokinetics (PK) and clinical activity of the glutaminase inhibitor CB-839 with the poly adenosine diphosphate ribose polymerase (PARP) inhibitor talazoparib in participants with advanced/metastatic solid tumors.
Interventions
- DRUG Talazoparib
- DRUG CB-839
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2019-05-20 |
| Est. Completion | 2020-07-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03875313
The ClinicalTrials.gov registry entry for NCT03875313 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Calithera Biosciences, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Talazoparib is the first listed.
NCT03875313 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03875313 about?
NCT03875313 is a clinical study titled "Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors". This is a Phase 1b/2 study to determine the recommended phase 2 dose (RP2D), safety and tolerability, pharmacokinetics (PK) and clinical activity of the glutaminase inhibitor CB-839 with the poly adenosine diphosphate ribose polymerase (PARP) inhibitor talazoparib in participants with advanced/metas...
What is the current status of trial NCT03875313?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2019-05-20. Estimated completion is 2020-07-29.
What interventions are being tested in trial NCT03875313?
The interventions under investigation include: Talazoparib (DRUG), CB-839 (DRUG).
Who is sponsoring clinical trial NCT03875313?
This trial is sponsored by Calithera Biosciences, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.